Why NovoCure Stock Leaped 4% Higher Today

Thursday morning NovoCure (NASDAQ: NVCR) published its first set of quarterly results for 2025, and they pleased more than a few investors. With that tailwind, the biotech's stock price rose in excess of 4%, easily topping the slightly over 2% increase of the S&P 500 index.For the first quarter, NovoCure recorded net revenue that was just shy of $155 million. That was a nearly 12% improvement over the same period of 2024. Compounding that, the biotech managed to narrow its generally accepted accounting principles (GAAP) net loss by roughly the same percentage; it landed at $34.4 million ($0.31 per share) against the Q1 2024 shortfall of $38.8 million. As a group, analysts tracking NovoCure's fortunes weren't expecting the company to do so well. Their collective estimate for net revenue was under $148 million; for headline net loss it was $0.49 per share. Continue reading

Apr 25, 2025 - 00:12

Why NovoCure Stock Leaped 4% Higher Today

Thursday morning NovoCure (NASDAQ: NVCR) published its first set of quarterly results for 2025, and they pleased more than a few investors. With that tailwind, the biotech's stock price rose in excess of 4%, easily topping the slightly over 2% increase of the S&P 500 index.

For the first quarter, NovoCure recorded net revenue that was just shy of $155 million. That was a nearly 12% improvement over the same period of 2024. Compounding that, the biotech managed to narrow its generally accepted accounting principles (GAAP) net loss by roughly the same percentage; it landed at $34.4 million ($0.31 per share) against the Q1 2024 shortfall of $38.8 million.

As a group, analysts tracking NovoCure's fortunes weren't expecting the company to do so well. Their collective estimate for net revenue was under $148 million; for headline net loss it was $0.49 per share.